Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18066325 | 0.80 | CHRNB2 (0.50) | MAPTGAAPOLBBRD4ALDH1A1 | |
| SCHEMBL23123 | 0.79 | BRD4 (0.64) | NPC1RAB9APOLBBRD4AURKA | |
| SCHEMBL8381773 | 0.78 | BRD4 (0.63) | NPC1RAB9APOLBBRD4AURKA | |
| SCHEMBL16619414 | 0.78 | NPC1 (0.48) | KDM4EDEGS1NPC1RAB9AKMT2A | |
| SCHEMBL7493930 | 0.77 | KMT2A (0.43) | MAPTKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL11842236 | 0.76 | MMP3 (0.65) | MAPTKDM4ESMN1; SMN2DEGS1MMP3 | |
| SCHEMBL6463473 | 0.75 | BRD4 (0.60) | NPC1RAB9ABRD4AURKARPS6KB1 | |
| SCHEMBL16619108 | 0.75 | NT5C2 (0.69) | HDAC8BRD4AURKB | |
| SCHEMBL16618808 | 0.74 | NT5C2 (0.67) | SMN1; SMN2DEGS1NPC1RAB9AKMT2A | |
| SCHEMBL2623134 | 0.72 | KCNQ3 (0.51) | NPC1RAB9AKMT2APOLBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | claimed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | claimed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | claimed |
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | disclosed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | NTPCR, NT5E, PNP | MAPT 4312/4885KDM4E 1444/4885SMN1; SMN2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.